文献速递中医内科中药与中成药合理使用

中草药治疗冠心病合并脑缺血性卒中患者的系统评价与Meta分析

Therapeutic potential of Chinese herbal medicine for coronary heart disease patients with cerebral ischemic stroke: a systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2025-07-16

结果显示CHM在提高总有效率、心电图表现及中医证候积分方面显著优于对照,并改善LVEF、MMSE、NIHSS及血脂指标,降低血黏度、纤维蛋白原和血小板聚集,安全性 Profiles 与单用西药相当。

要点

  • CHM可显著提高冠心病合并脑缺血性卒中患者的总有效率、心电图表现及中医证候积分。
  • CHM改善LVEF、MMSE、NIHSS及TC、TG、LDL-C、HDL-C等血脂指标。
  • CHM降低血黏度、纤维蛋白原和血小板聚集,安全性 Profiles 与单用西药相当。

核心结论

  • CHM在冠心病合并脑缺血性卒中患者管理中显示出更优疗效,并可能改善神经损伤、血脂谱及血液流变学参数,同时未增加不良反应风险。

主要发现

  • CHM显著提高总有效率、心电图表现及中医证候积分。
  • CHM显著改善LVEF、MMSE和NIHSS。
  • CHM对TC、TG、LDL-C和HDL-C等血脂指标产生积极影响。
  • CHM在降低血黏度、纤维蛋白原和血小板聚集方面尤为有效。
  • CHM安全性 Profiles 与单用常规西药治疗相当。

临床怎么用

  • 在冠心病合并脑缺血性卒中患者中,可考虑在常规西药治疗基础上联合CHM以改善疗效、神经功能、血脂及血液流变学指标。

局限性

  • 研究质量存在局限性且可能存在报告偏倚,上述发现需未来严格设计的大规模高质量RCT进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This research sought to demonstrate potential therapeutic strategies for coronary heart disease (CHD) patients with cerebral ischemic stroke (CIS) by rigorously evaluating the efficacy and safety of Chinese Herbal Medicine (CHM) through meta-analysis. METHODS: A broad search approach was applied to obtain pertinent articles from both domestic and international databases, covering publications up to 31 December 2024. Using RevMan software (Version 5.4), a systematic review and meta-analysis were conducted to assess the efficacy and safety of CHM in treating CHD patients with CIS. RESULTS: In the meta-analysis, 18 trails were analyzed, encompassing 2,202 patients in total. The aggregated findings indicated that the utilization of CHM improved the overall effective rate, ECG performance and TCM scores significantly. Furthermore, the CHM therapy demonstrated significant improvements in LVEF, MMSE, and NIHSS. Additionally, the CHMs therapy positively influenced lipid profiles, specifically TC, TG, LDL-C, and HDL-C. Notably, the application of CHM during the intervention was particularly effective in reducing blood viscosity, fibrinogen and platelet aggregation. Importantly, the CHM therapy was found to provide comparable safety profile to that of conventional western medicine treatment (WM) alone. CONCLUSION: The CHM demonstrated superior efficacy in the management of CHD patients with CIS. Concurrently, the CHM showed potential for improving neurological damage, lipid profiles, and positively affecting hemorheological parameters, all while minimizing the risk of adverse effects. Even so, because of the limitations in study quality and the potential for reporting bias, it is crucial that these findings require to be further validated through rigorous, large-scale, and high-quality RCT in future research.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Du R, Ao Y, Wang Y, et al. Therapeutic potential of Chinese herbal medicine for coronary heart disease patients with cerebral ischemic stroke: a systematic review and meta-analysis. Front Pharmacol. 2025. PMID: 40741003. doi:10.3389/fphar.2025.1578783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。